Published by the European Cannabis Institute · Educational and professional reference content.
Capsules can offer discreet administration and unit dosing, but the apparent simplicity of the dosage form can hide important formulation and manufacturing risks.
Dose uniformity
Cannabinoids may be dissolved, suspended or carried in a powder blend. Each approach requires evidence that every capsule delivers the intended amount throughout the batch.
Excipient and shell compatibility
Oils, surfactants, antioxidants and capsule-shell materials can interact over time. Development should evaluate leakage, brittleness, migration, oxidation and moisture sensitivity.
Manufacturing controls
Fill-weight checks alone do not prove content uniformity. In-process controls should be linked to validated mixing, hold-time, filling and cleaning processes.
Stability and packaging
Protection from oxygen, light and temperature may be necessary. Stability protocols should assess potency, degradants, physical appearance, dissolution or release behaviour where relevant, and microbial quality.
ECI perspective
Strong cannabis quality systems connect scientific evidence, product knowledge, validated methods and controlled operations. Organisations should document the rationale for their decisions and update it as evidence, processes and regulatory expectations evolve.
References
- Ph. Eur. — Capsules, General Monograph
- EU GMP Part I, Chapter 4 — Documentation
- ICH Q6A — Specifications for New Drug Substances and Products
Confirm the current effective version and national applicability before operational, regulatory or clinical use.